Mario Negri Institute for Pharmacological Research
Phase 3
2003-03-01
End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have
increased morbidity and mortality mostly because of a dramatic excess of cardiovascular
disease. Thus, preventing or limiting the progression of chronic nephropathies, in addition
to limit the incidence of ESRD, may also postpone death. Drugs that inhibit the renin
angiotensin system, such as Angiotensin-Converting-Enzyme inhibitors (ACEi) and Angiotensin
II receptor antagonists (ATA), are reno- and cardio-protective in the long-term. There are
data that statins,in addition to limit cardiovascular events may have specific
reno-protective properties.
Thus we designed a study aimed to evaluate whether statins associated to ACEi and ATA may
have an additional reno-protective effect.
ESPLANADE is a multicenter, prospective, randomized, parallel group study in which, after 2
months treatment with ACEi and ATA, two groups of 90 patients, with or without type 2
diabetes, are randomized to 6 months Fluvastatin (40 or 80 mg/day) treatment YES or NO.Twenty
Italian Nephrology Units are involved in the trial. The study is fully coordinated by the
Clinical Research Center for Rare Disease Aldo e Cele Daccò, Villa Camozzi, Ranica.
Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors
Withdrawn
Novartis
Phase 3
2006-10-01
The purpose of the study is to determine the effect of fluvastatin on penile arterial blood
flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.
Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors
Withdrawn
University Hospital, Saarland
Phase 3
2006-10-01
The purpose of the study is to determine the effect of fluvastatin on penile arterial blood
flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.